In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
OBJECTIVE
The aim of the study was to compare the in vitro quality of buffy coat-derived platelet concentrates (PC) during extended storage in plasma or additive solution in three different storage bags.


METHODS
A pooled and split design was chosen so that identical PCs were produced in either 100% plasma, 70% PASII : 30% plasma or 70% CompoSol : 30% plasma (n = 6 each). This was repeated for three different manufacturers' platelet storage bags (Fresenius, Baxter and Pall). PCs were sampled on days 1, 5, 7 and 9 of storage and tested in vitro using a variety of tests of platelet function. For each bag type, storage in PASII or Composol was compared with plasma (data taken across the entire storage period), and differences occurring with time were analysed for all storage media.


RESULTS
The pH of all PCs was > 6.8 at day 9 of storage. In vitro platelet function, as assessed by markers of platelet activation and metabolism, of PCs stored in CompoSol appeared to be similar to that of PCs stored in plasma over 9 days of storage. In contrast, PCs stored in PASII tended to have significantly higher levels of platelet activation (almost a twofold increase in % platelets positive for CD62P by day 5) and lower hypotonic shock response (approximately 40%, by day 7) compared to either PCs stored in 100% plasma or 70% CompoSol. The magnitude of the differences observed between platelet storage media appeared to be dependent on the type of platelet storage bag with the highest degree of platelet activation and lowest hypotonic shock response values being observed in Fresenius bags in combination with PASII.


CONCLUSIONS
The maintenance of platelet function in vitro during extended storage of PCs in platelet additive solutions is dependent on the combination of type of additive solution and type of platelet storage bag. For all bag types studied, storage in PASII resulted in poorer platelet function in vitro.
Cardigan
R
R
Components Development Laboratory, NHS Blood and Transplant, Brentwood, UK. rebecca.cardigan@nbs.nhs.uk
Sutherland
J
J
Garwood
M
M
Bashir
S
S
Turner
C
C
Smith
K
K
Hancock
V
V
Wiltshire
M
M
Pergande
C
C
Williamson
L M
LM
D000085:Acetates / Q000494:pharmacology / Q000592:standards; D001792:Blood Platelets / Q000166:cytology*; D001793:Blood Preservation / Q000379:methods* / Q000592:standards; D002951:Citrates / Q000494:pharmacology / Q000592:standards; D006801:Humans; D019999:Pharmaceutical Solutions / Q000737:chemistry / Q000494:pharmacology / Q000592:standards*; D010949:Plasma; D010979:Platelet Function Tests; D010983:Plateletpheresis; D019064:Product Packaging / Q000592:standards; D012965:Sodium Chloride / Q000494:pharmacology / Q000592:standards; D013997:Time Factors
D000085:Acetates; D002951:Citrates; C436265:PAS-2 salt solution; D019999:Pharmaceutical Solutions; D012965:Sodium Chloride